Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
; : 1458-1461, 2018.
Article
in En
| WPRIM
| ID: wpr-717508
Responsible library:
WPRO
ABSTRACT
Myxofibrosarcoma is a rare tumor, refractory to cytotoxic chemotherapy and radiotherapy. Pembrolizumab is an innovative immunotherapy drug consisting of programmed death receptor ligand 1 antibody proven to be useful for numerous types of cancer cells. A patient had been diagnosed with metastatic myxofibrosarcoma, refractory to radiotherapy and conventional cytotoxic chemotherapy. The patient achieved a partial response during palliative chemotherapy with pembrolizumab for 14 cycles. To the best of our knowledge, this is the first case report demonstrating the efficacy of pembrolizumab for refractory myxofibrosarcoma.
Key words
Full text:
1
Database:
WPRIM
Main subject:
Radiotherapy
/
Sarcoma
/
Drug Therapy
/
Immunotherapy
Limits:
Humans
Language:
En
Journal:
Cancer Research and Treatment
Year:
2018
Document type:
Article